Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Pyridostigmine for Emergence Agitation in Pediatric Strabismus Surgery
NCT06035757Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Countries
- 1
- Sponsor
- Konkuk University Medical Center
- Modality
- Biodegradable Polymers, Small Molecules
- Drugs
- Sugammadex
- Conditions
- emergence delirium (ED)
01
Overview
Phase 4, randomised trial of Sugammadex in emergence delirium (ED) (2 arms), sponsored by Konkuk University Medical Center. Primary endpoint: Incidence of Emergence Agitation at 45 minutes. Started Dec 2023; status: completed.
02
Design
2 arms- Study design
- Randomized
group pyridostigmine
Pyridostigmine administered at the end of surgery based on TOF count.
group sugammadex
Sugammadex administered at the end of surgery based on TOF or PTC count.
03
Who it enrols
Pediatric patients aged 4-7 scheduled for elective strabismus surgery with ASA classification 1-2, excluding those with impaired liver or kidney function, myasthenia gravis, cardiovascular disease, or history of drug allergy.
04
Endpoints
Primary
Incidence of Emergence Agitation
Beyond the preview
Go deeper on NCT06035757.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035757.